Clinical effect of molecular targeted drug on patients with metastatic renal cell carcinoma and the impact on their quality of lives
CHEN Weidong;LIU Huaimin;ZHANG Fengxian;MA Ke;Department of Nephrology,the Fourth People's Hospital of Shangqiu City;Department of Integrated Traditional Chinese and Western Medicine,He'nan Cancer Hospital;Department of Oncology,the Fourth People's Hospital of Shangqiu City;
Objective To explore the clinical effect of molecular targeted drug sunitinib on patients with metastatic renal cell carcinoma(m RCC) and the impact on their quality of lives. Method Clinical data of 75 patients with m RCC were collected and analyzed retrospectively. The patients were divided into control group(n=32) and observation group(n=43) according to the different treatment regimens, the patients in control group received interleukin-2(IL-2) and recombinant human interferon(IFNα-2 b), and the patients in observation group received sunitinib. The efficacy, quality of life and adverse reactions were compared. Result After treatment, the disease control rate(DCR) in observation group was 76.74%, which was significantly higher than that in control group of 53.12%(P0.05). Before treatment, there was no significant difference in function, symptoms, special indexes or total health condition between two groups(P0.05).After treatment, the patients' quality of lives were decreased in both groups, scores of physical function were decreased,scores of fatigue, nausea and vomiting, poor appetite, constipation and diarrhea were all increased and the total health score was decreased, all changes of the scores were significantly different compared to those before treatment(P0.05).There was no significant difference in any score of live quality between two groups after treatment(P0.05). For the adverse reactions, compared with control group, the occurrence rates of fever, liver dysfuncion and fatigue were significantly lower and the occurrence rates of skin-mucous membrane reactions, hypertension and thyroid hypofunction were significantly higher in observation group(P0.05). After symptomatic treatment, all adverse reactions were controlled and they were tolerable for the patients. Conclusion Sunitinib is effective for m RCC, with tolerable adverse reactions, which is worthy of widely clinical use.
【CateGory Index】： R737.11